We found that the insulin-treated persons with type 1 diabetes displayed a Th2-biased immune phenotype with a high proportion of effector CD4+ T cells and CD19+ B cells, and a downregulation of Th1 serum cytokines, irrespective of their capacity for glycemic control [47]. This evidence concerns the gene CD19 and type 1 diabetes mellitus.